Alzinova receives approximately SEK 2,8 million through the exercise of the warrants of series TO2 2020/2022
In October 2020, Alzinova AB (publ) (“Alzinova” or the “Company”) carried out an issue of units with pre-emption rights for the shareholders (the “Rights Issue”), as well as an issue of units without pre-emption rights for the shareholders to the guarantors in the Rights Issue for their guaranteed commitments (the “Directed Issue”). The units issued in the Rights Issue and the Directed Issue consisted of shares and warrants of series TO2 2020/2022 (the “warrants”). The exercise period for the warrants ran from and including January 24, 2022 up to and including February 7, 2022. In total, 867 590 warrants were exercised for subscription of new shares, corresponding to an exercise rate of approximately 11 percent.
In total, 867 590 warrants were exercised, corresponding to approximately 11 percent of the total amount of warrants issued in the Rights Issue and the Directed Issue, for subscription of 433 795 shares. Two warrants entailed a right to subscribe for one new share in Alzinova to a subscription price of SEK 6.50 per share. Through the exercised warrants, Alzinova is thereby provided approximately SEK 2.8 million before issuing costs.
Number of shares and share capital
Through the exercise of the warrants, the number of shares in Alzinova increases with 433 795 shares, from 15 775 724 to 16 209 519 shares. The share capital increases with SEK 114 088,085, from SEK 4 149 015,412 to SEK 4 263 103,497. For existing shareholders who have not exercised any warrants, the dilution amounts to approximately 3 percent based on the number of shares in Alzinova after the exercise of the warrants.
Advisers
Redeye AB acts as financial adviser, Fredersen Advokatbyrå AB acts as legal adviser and Hagberg Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue.
For more information, please contact:
Kristina Torfgård, VD Alzinova
Tel: +46 70 846 79 75
e-mail: kristina.torfgard@alzinova.com
About Alzinova
Alzinova AB (publ) is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 768-532 822. For more information about Alzinova, please visit: www.alzinova.com